<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209791</url>
  </required_header>
  <id_info>
    <org_study_id>14-1287</org_study_id>
    <nct_id>NCT03209791</nct_id>
  </id_info>
  <brief_title>Ethanol Induces Skeletal Muscle Autophagy</brief_title>
  <official_title>Mechanisms of Skeletal Muscle Proteolysis With Ethanol Consumption: an Integrated Molecular Metabolic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to
      degrade MAA adducts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Ethanol mediated modification of skeletal muscle proteins to form MAA adducts
      that in turn induce skeletal muscle autophagy.

      Patients with alcoholic steatosis, hepatitis and cirrhosis (n=10 each) will be recruited from
      the liver transplant nutrition clinic or the hepatology inpatient service and their body
      composition quantified using anthropometry, bioelectrical impedance analysis, CT image
      analysis and DEXA if available.

      Control Subjects. Controls will be recruited by advertisement. All control subjects will have
      a normal clinical history, physical examination, and screening chemistries. They will not
      have any significant medical conditions requiring the use of medications. Their nutritional
      status within 20% of normal as defined by ideal body weight.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal Muscle Autophagy</measure>
    <time_frame>4 hours</time_frame>
    <description>We will measure Malonyldialdehyde Acetaldehyde protein adducts to see skeletal muscle proteolysis during a one time muscle biopsy</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Alcoholic Steatosis</arm_group_label>
    <description>This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis</arm_group_label>
    <description>This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatohepatitis</arm_group_label>
    <description>This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>Biopsy will be done on the Vastus Lateralis muscle in all groups</description>
    <arm_group_label>Alcoholic Steatosis</arm_group_label>
    <arm_group_label>Cirrhosis</arm_group_label>
    <arm_group_label>Steatohepatitis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically characterized patients with alcoholic steatosis, hepatitis and cirrhosis
        (n=10 each) will be recruited from the liver transplant nutrition clinic or the hepatology
        inpatient service and their body composition quantified using protocols already established
        by the PI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Alcoholic liver disease:

          -  clinical, biochemical, imaging criteria and liver biopsy where available

          -  Age 18 - 65 years old

        Controls:

          -  Serum liver transaminases (i.e. ALT and AST) 40 IU/L

          -  Normal liver ultrasound

          -  Age 18 - 65 years old

        Exclusion Criteria:

        For both groups - alcoholic liver disease and controls:

          -  Poorly controlled diabetes mellitus (HbA1C&gt;9.5 g/dl)

          -  Untreated Hyper- / hypo- thyroidism

          -  Patients on dialysis, renal disease with serum creatinine 1.5 mg/dL

          -  Active intravenous drug use

          -  History of bowel surgery or gastric bypass surgery

          -  Medications known to alter muscle protein metabolism (i.e. corticosteroids, tamoxifen,
             high-dose estrogen, testosterone or anabolic steroids)

          -  Metastatic disease, Advanced cardiac or pulmonary disease

          -  Pregnancy

          -  Coagulopathy- INR &gt;1.4 and platelet count &lt;80,000/ml.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivasan Dasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revathi Penumatsa, MPH</last_name>
    <phone>2164450688</phone>
    <email>penumar@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Bellar, MSLA</last_name>
    <phone>2166365247</phone>
    <email>bellara@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Revathi Penumatsa</last_name>
      <phone>216-445-0688</phone>
      <email>penumar@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Annette Bellar</last_name>
      <phone>2166365247</phone>
      <email>bellara@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

